Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1998;25(1):49–56.

Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.

J E Tcheng 1
PMCID: PMC325502  PMID: 9566064

Abstract

During the past 2 decades, advances in molecular and cellular biology have greatly expanded our understanding of the critical role of platelets in the pathogenesis of acute coronary syndromes. This work has suggested that aggressive platelet inhibition might reduce cardiovascular morbidity and mortality rates beyond the reductions already achieved with aspirin and other conventional therapies. Researchers in basic science laboratories have identified a specific platelet receptor, the glycoprotein IIb/IIIa integrin, which serves as the mediator, or final common pathway, leading to platelet aggregation. This glycoprotein receptor is a logical target for the development of antagonists to inhibit thrombosis. A number of these antagonists have been tested in clinical trials involving coronary intervention, unstable angina, and acute myocardial infarction. Herein, I present some of the rationale behind the investigation of these agents, as well as some issues to be considered with regard to the future of this exciting new class of drugs.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguirre F. V., Topol E. J., Ferguson J. J., Anderson K., Blankenship J. C., Heuser R. R., Sigmon K., Taylor M., Gottlieb R., Hanovich G. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation. 1995 Jun 15;91(12):2882–2890. doi: 10.1161/01.cir.91.12.2882. [DOI] [PubMed] [Google Scholar]
  2. Ambrose J. A., Winters S. L., Stern A., Eng A., Teichholz L. E., Gorlin R., Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985 Mar;5(3):609–616. doi: 10.1016/s0735-1097(85)80384-3. [DOI] [PubMed] [Google Scholar]
  3. Berkowitz S. D., Harrington R. A., Rund M. M., Tcheng J. E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 1997 Feb 18;95(4):809–813. doi: 10.1161/01.cir.95.4.809. [DOI] [PubMed] [Google Scholar]
  4. Cairns J. A., Gill J., Morton B., Roberts R., Gent M., Hirsh J., Holder D., Finnie K., Marquis J. F., Naqvi S. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation. 1996 Oct 1;94(7):1553–1560. doi: 10.1161/01.cir.94.7.1553. [DOI] [PubMed] [Google Scholar]
  5. Coller B. S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985 Jul;76(1):101–108. doi: 10.1172/JCI111931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Coller B. S., Anderson K. M., Weisman H. F. The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Haemostasis. 1996 Oct;26 (Suppl 4):285–293. doi: 10.1159/000217309. [DOI] [PubMed] [Google Scholar]
  7. D'Souza S. E., Haas T. A., Piotrowicz R. S., Byers-Ward V., McGrath D. E., Soule H. R., Cierniewski C., Plow E. F., Smith J. W. Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell. 1994 Nov 18;79(4):659–667. doi: 10.1016/0092-8674(94)90551-7. [DOI] [PubMed] [Google Scholar]
  8. Ellis S. G., Bates E. R., Schaible T., Weisman H. F., Pitt B., Topol E. J. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol. 1991 May;17(6 Suppl B):89B–95B. doi: 10.1016/0735-1097(91)90943-4. [DOI] [PubMed] [Google Scholar]
  9. Ferguson J. J. Meeting highlights: 46th Annual Scientific Sessions of the American College of Cardiology. Circulation. 1997 Jul 15;96(2):367–371. doi: 10.1161/01.cir.96.2.367. [DOI] [PubMed] [Google Scholar]
  10. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med. 1986 Oct 16;315(16):983–989. doi: 10.1056/NEJM198610163151602. [DOI] [PubMed] [Google Scholar]
  11. Gold H. K., Coller B. S., Yasuda T., Saito T., Fallon J. T., Guerrero J. L., Leinbach R. C., Ziskind A. A., Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988 Mar;77(3):670–677. doi: 10.1161/01.cir.77.3.670. [DOI] [PubMed] [Google Scholar]
  12. Harrington R. A. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1997 Aug 18;80(4A):34B–38B. doi: 10.1016/s0002-9149(97)00575-4. [DOI] [PubMed] [Google Scholar]
  13. Harrington R. A., Kleiman N. S., Kottke-Marchant K., Lincoff A. M., Tcheng J. E., Sigmon K. N., Joseph D., Rios G., Trainor K., Rose D. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995 Dec 15;76(17):1222–1227. doi: 10.1016/s0002-9149(99)80345-2. [DOI] [PubMed] [Google Scholar]
  14. Hynes R. O. Integrins: a family of cell surface receptors. Cell. 1987 Feb 27;48(4):549–554. doi: 10.1016/0092-8674(87)90233-9. [DOI] [PubMed] [Google Scholar]
  15. Kiss R. G., Stassen J. M., Deckmyn H., Roskams T., Gold H. K., Plow E. F., Collen D. Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. Arterioscler Thromb. 1994 Mar;14(3):375–380. doi: 10.1161/01.atv.14.3.375. [DOI] [PubMed] [Google Scholar]
  16. Lefkovits J., Plow E. F., Topol E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995 Jun 8;332(23):1553–1559. doi: 10.1056/NEJM199506083322306. [DOI] [PubMed] [Google Scholar]
  17. Lincoff A. M., Tcheng J. E., Califf R. M., Bass T., Popma J. J., Teirstein P. S., Kleiman N. S., Hattel L. J., Anderson H. V., Ferguson J. J. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol. 1997 Feb 1;79(3):286–291. doi: 10.1016/s0002-9149(96)00749-7. [DOI] [PubMed] [Google Scholar]
  18. Ohman E. M., Kleiman N. S., Gacioch G., Worley S. J., Navetta F. I., Talley J. D., Anderson H. V., Ellis S. G., Cohen M. D., Spriggs D. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997 Feb 18;95(4):846–854. doi: 10.1161/01.cir.95.4.846. [DOI] [PubMed] [Google Scholar]
  19. Phillips D. R., Charo I. F., Parise L. V., Fitzgerald L. A. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988 Apr;71(4):831–843. [PubMed] [Google Scholar]
  20. Phillips D. R., Charo I. F., Scarborough R. M. GPIIb-IIIa: the responsive integrin. Cell. 1991 May 3;65(3):359–362. doi: 10.1016/0092-8674(91)90451-4. [DOI] [PubMed] [Google Scholar]
  21. Phillips D. R., Teng W., Arfsten A., Nannizzi-Alaimo L., White M. M., Longhurst C., Shattil S. J., Randolph A., Jakubowski J. A., Jennings L. K. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997 Sep 2;96(5):1488–1494. doi: 10.1161/01.cir.96.5.1488. [DOI] [PubMed] [Google Scholar]
  22. Pytela R., Pierschbacher M. D., Ginsberg M. H., Plow E. F., Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. Science. 1986 Mar 28;231(4745):1559–1562. doi: 10.1126/science.2420006. [DOI] [PubMed] [Google Scholar]
  23. Seydoux C., Goy J. J., Davies G. Platelet and neutrophil imaging techniques in the investigation of the response to thrombolytic therapy and the no-reflow phenomenon. Am Heart J. 1993 Apr;125(4):1142–1147. doi: 10.1016/0002-8703(93)90127-u. [DOI] [PubMed] [Google Scholar]
  24. Tcheng J. E. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996 Aug 14;78(3A):35–40. doi: 10.1016/s0002-9149(96)00490-0. [DOI] [PubMed] [Google Scholar]
  25. Tcheng J. E., Harrington R. A., Kottke-Marchant K., Kleiman N. S., Ellis S. G., Kereiakes D. J., Mick M. J., Navetta F. I., Smith J. E., Worley S. J. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 1995 Apr 15;91(8):2151–2157. doi: 10.1161/01.cir.91.8.2151. [DOI] [PubMed] [Google Scholar]
  26. Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994 Apr 9;343(8902):881–886. doi: 10.1016/s0140-6736(94)90007-8. [DOI] [PubMed] [Google Scholar]
  27. Wilentz J. R., Sanborn T. A., Haudenschild C. C., Valeri C. R., Ryan T. J., Faxon D. P. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987 Mar;75(3):636–642. doi: 10.1161/01.cir.75.3.636. [DOI] [PubMed] [Google Scholar]
  28. Willerson J. T., Golino P., Eidt J., Campbell W. B., Buja L. M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation. 1989 Jul;80(1):198–205. doi: 10.1161/01.cir.80.1.198. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES